Browse drugs

…etabolizers is not affected by an upfront 30% dose reduction of irinotecan. Therefore, UGT1A1 genotype-guided dosing of irinotecan can be …

…e its potential impact in patients with breast cancer receiving sacituzumab govitecan.Material and Methods We conducted a retrospective study in two …

…ns (3.6%), 20 irinotecan (2.0%), 196 paclitaxel (16.6%), and 21 trastuzumab (3.1%).Conclusion and Relevance A simulation analysis of a dose…

…acterial toxicity independent of the SN-38 active metabolite of irinotecan. By producing indole-3-acetate (I3A), Bacteroides intestinalis …

…c MGMT-deficient G1/G2 PanNET treated with TMZ, with or without capecitabine, reportedly experienced histological progression to G3 disease …

…systemic palliative chemotherapy with NALIRIFOX, mFOLFIRINOX or Gem/NabP between January 2021 and July 2024. Key eligibility criteria re…

…oadjuvant FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, oxaliplatin) chemotherapy for borderline resectable pancreatic adenocarcino…

…uctured pharmacist-led follow-up. The excellent tolerability of XELOX, with no need for rescue therapy, suggests this subgroup could …

…, 48.7% (19) started fluoropyrimidines: 52.6% (10) started with capecitabine, 26.3% (five) combined with oxaliplatin, 15.8% (three) started …

…demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clini…

…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…

…is cohort, high AXL predicted worse OS in patients treated with fluorouracil, leucovorin, and oxaliplatin/fluorouracil, leucovorin, and irin…